MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 September 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company’s Chief Financial Officer (CFO), effective today. “We look forward to Abby’s contributions whose ...
– Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data – Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 23 September 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Highlights MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 July 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2024 (Q4 ...
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 24 July 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. Details are ...
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 17 July ...
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 13 June 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present a company overview at the MST Access ‘Hidden Gems in Life Sciences’ ...
Webcast Presentation
– New bioMUSE Data Informs ATH434-202 Study Endpoints – – Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 May 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, ...
– ATH434-201 Trial on Track to Complete in November 2024 – – Top-Line Data Expected in January 2025 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 8 May 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an ...
Receive news from Alterity Therapeutics
